These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11721637)

  • 1. Proteomic approaches to biomarker discovery in prostate and bladder cancers.
    Adam BL; Vlahou A; Semmes OJ; Wright GL
    Proteomics; 2001 Oct; 1(10):1264-70. PubMed ID: 11721637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery.
    Tanase CP; Codrici E; Popescu ID; Mihai S; Enciu AM; Necula LG; Preda A; Ismail G; Albulescu R
    Oncotarget; 2017 Mar; 8(11):18497-18512. PubMed ID: 28061466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass spectrometry-based expression profiling of clinical prostate cancer.
    Wright ME; Han DK; Aebersold R
    Mol Cell Proteomics; 2005 Apr; 4(4):545-54. PubMed ID: 15695425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer.
    Latosinska A; Frantzi M; Vlahou A; Mischak H
    Proteomics Clin Appl; 2013 Dec; 7(11-12):779-93. PubMed ID: 23970371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.
    Nguyen EV; Centenera MM; Moldovan M; Das R; Irani S; Vincent AD; Chan H; Horvath LG; Lynn DJ; Daly RJ; Butler LM
    Mol Cell Proteomics; 2018 Aug; 17(8):1470-1486. PubMed ID: 29632047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis.
    Wright GL
    Expert Rev Mol Diagn; 2002 Nov; 2(6):549-63. PubMed ID: 12465452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Capillary electrophoresis coupled to mass spectrometry for proteome analysis. An innovative diagnostic method for prostate and bladder cancer].
    Wittke S; Schiffer E; Bauer HW
    Urologe A; 2007 Jul; 46(7):733-9. PubMed ID: 17318473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer stroma proteome expression profile of superficial bladder transitional cell carcinoma and biomarker discovery.
    Niu HT; Yang CM; Jiang G; Xu T; Cao YW; Zhao J; Wang XS
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1273-82. PubMed ID: 21706132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomics for the identification of new prostate cancer biomarkers.
    Ornstein DK; Tyson DR
    Urol Oncol; 2006; 24(3):231-6. PubMed ID: 16678055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology.
    Fredolini C; Meani F; Luchini A; Zhou W; Russo P; Ross M; Patanarut A; Tamburro D; Gambara G; Ornstein D; Odicino F; Ragnoli M; Ravaggi A; Novelli F; Collura D; D'Urso L; Muto G; Belluco C; Pecorelli S; Liotta L; Petricoin EF
    AAPS J; 2010 Dec; 12(4):504-18. PubMed ID: 20549403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel alternative splicing biomarkers for breast cancer with LC/MS/MS and RNA-Seq.
    Zhang F; Deng CK; Wang M; Deng B; Barber R; Huang G
    BMC Bioinformatics; 2020 Dec; 21(Suppl 9):541. PubMed ID: 33272210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder Urothelial Carcinoma Diagnosis by Liquid-based Cytology.
    Lee H; Kim K; Woo J; Park J; Kim H; Lee KE; Kim H; Kim Y; Moon KC; Kim JY; Park IA; Shim BB; Moon JH; Han D; Ryu HS
    Mol Cell Proteomics; 2018 Sep; 17(9):1788-1802. PubMed ID: 29950347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform.
    Schiffer E; Mischak H; Theodorescu D; Vlahou A
    World J Urol; 2008 Feb; 26(1):67-74. PubMed ID: 18175124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer.
    Chen CL; Chung T; Wu CC; Ng KF; Yu JS; Tsai CH; Chang YS; Liang Y; Tsui KH; Chen YT
    Mol Cell Proteomics; 2015 Sep; 14(9):2466-78. PubMed ID: 26081836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Proteome of Primary Prostate Cancer.
    Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
    Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic investigation of intra-tumor heterogeneity using network-based contextualization - A case study on prostate cancer.
    Goh WWB; Zhao Y; Sue AC; Guo T; Wong L
    J Proteomics; 2019 Aug; 206():103446. PubMed ID: 31323421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.
    Moreira JM; Ohlsson G; Gromov P; Simon R; Sauter G; Celis JE; Gromova I
    Mol Cell Proteomics; 2010 Jan; 9(1):161-77. PubMed ID: 19783793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parafilm-assisted microdissection: a sampling method for mass spectrometry-based identification of differentially expressed prostate cancer protein biomarkers.
    Quanico J; Franck J; Gimeno JP; Sabbagh R; Salzet M; Day R; Fournier I
    Chem Commun (Camb); 2015 Mar; 51(22):4564-7. PubMed ID: 25490716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics in diagnosis of prostate cancer.
    Davalieva K; Polenakovic M
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
    Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF
    J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.